SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Baecklund Johan)
 

Sökning: WFRF:(Baecklund Johan) > Comparative effecti...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00005743naa a2200685 4500
001oai:lup.lub.lu.se:aed6dab2-3c01-4dcc-be0b-b122170bb316
003SwePub
008200330s2019 | |||||||||||000 ||eng|
009oai:gup.ub.gu.se/286000
009oai:prod.swepub.kib.ki.se:142177964
0247 a https://lup.lub.lu.se/record/aed6dab2-3c01-4dcc-be0b-b122170bb3162 URI
0247 a https://doi.org/10.1093/rheumatology/key4332 DOI
0247 a https://gup.ub.gu.se/publication/2860002 URI
0247 a http://kipublications.ki.se/Default.aspx?queryparsed=id:1421779642 URI
040 a (SwePub)lud (SwePub)gud (SwePub)ki
041 a engb eng
042 9 SwePub
072 7a art2 swepub-publicationtype
072 7a ref2 swepub-contenttype
1001 a Frisell, Thomasu Karolinska Institutet,Karolinska Institute4 aut
2451 0a Comparative effectiveness of abatacept, rituximab, tocilizumab and TNFi biologics in RA : Results from the nationwide Swedish register
264 c 2019-01-21
264 1b Oxford University Press (OUP),c 2019
300 a 11 s.
520 a Objectives: Current guidelines rank abatacept, rituximab, tocilizumab and TNF-inhibitors (TNFi) as having equal effectiveness for the treatment of RA, at least as second line therapies. These recommendations are mainly based on meta-analysis of randomized controlled trials, with few direct drug-drug comparisons. Our objective was to compare the real-world absolute and relative effectiveness among RA patients starting any of the available biologic DMARDs (bDMARDs). Methods: We used the Swedish Rheumatology Register to identify patients with RA initiating TNFi, rituximab, abatacept or tocilizumab in 2010-2016 as first bDMARD (n = 9333), or after switch from TNFi as first bDMARD (n = 3941). National Swedish registers provided additional covariates and censoring events. Effectiveness was assessed 3 and 12 months after treatment start, as the proportion remaining on therapy and with EULAR Good Response, HAQ improvement >0.2, zero swollen/tender joints and CDAI remission. Adjusted differences were estimated with multivariable linear regression. Results: Patients starting non-TNFi (vs TNFi) as first bDMARD had a higher proportion remaining on drug and reaching most response outcomes as first bDMARD (1-year EULAR Good Response/HAQ improvement: TNFi 24.9/25.4%, rituximab 28.6/37.2%, abatacept 31.9/33.7%, tocilizumab 50.9/43.1%). After switch from a first TNFi, rituximab and tocilizumab, but not abatacept, were associated with significantly better response measures than TNFi (1-year EULAR Good Response/HAQ improvement: TNFi 11.6/16.1%, rituximab 24.8/33.2%, abatacept 13.1/17.5%, tocilizumab 34.1/29.4%). Differences remained significant after adjusting for potential confounders. Conclusion: Treatment outcomes among RA patients treated in Swedish clinical practice are in line with a superior effectiveness of non-TNFi bDMARDs, in particular tocilizumab and rituximab, compared with TNFi.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Reumatologi och inflammation0 (SwePub)302102 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Rheumatology and Autoimmunity0 (SwePub)302102 hsv//eng
650 7a MEDICIN OCH HÄLSOVETENSKAPx Medicinska och farmaceutiska grundvetenskaperx Farmakologi och toxikologi0 (SwePub)301022 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Basic Medicinex Pharmacology and Toxicology0 (SwePub)301022 hsv//eng
653 a abatacept
653 a anti-TNF
653 a biologics
653 a effectiveness
653 a rheumatoid arthritis
653 a rituximab
653 a tocilizumab
653 a treatment outcome
7001 a Dehlin, Mats,d 1968u Gothenburg University,Göteborgs universitet,University of Gothenburg,Institutionen för medicin, avdelningen för reumatologi och inflammationsforskning,Institute of Medicine, Department of Rheumatology and Inflammation Research4 aut0 (Swepub:gu)xdehma
7001 a Di Giuseppe, Danielau Karolinska Institutet,Karolinska Institute4 aut
7001 a Feltelius, Nilsu Swedish medical products agency4 aut
7001 a Turesson, Carlu Lund University,Lunds universitet,Reumatologi och molekylär skelettbiologi,Sektion III,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Internmedicin - epidemiologi,Forskargrupper vid Lunds universitet,Rheumatology,Section III,Department of Clinical Sciences, Lund,Faculty of Medicine,Internal Medicine - Epidemiology,Lund University Research Groups,Skåne University Hospital4 aut0 (Swepub:lu)med-ctn
7001 a Askling, Johanu Karolinska Institutet,Karolinska Institute4 aut
7001 a Ernestam, S.u Karolinska Institutet4 aut
7001 a Klareskog, L.u Karolinska Institutet4 aut
7001 a Nisell, R.4 aut
7001 a Baecklund, E.4 aut
7001 a Kastbom, A.4 aut
7001 a Jacobsson, L.4 aut
7001 a Lindqvist, E.4 aut
7001 a d'Elia, H. F.4 aut
7001 a Rantapaa-Dahlqvist, S4 aut
7102 a Karolinska Institutetb Karolinska Institute4 org
7102 a ARTIS Study Group
7730 t Rheumatology (United Kingdom)d : Oxford University Press (OUP)g 58:8, s. 1367-1377q 58:8<1367-1377x 1462-0324x 1462-0332
8564 u http://dx.doi.org/10.1093/rheumatology/key433y FULLTEXT
8564 u https://academic.oup.com/rheumatology/article-pdf/58/8/1367/28984616/key433.pdf
8564 8u https://lup.lub.lu.se/record/aed6dab2-3c01-4dcc-be0b-b122170bb316
8564 8u https://doi.org/10.1093/rheumatology/key433
8564 8u https://gup.ub.gu.se/publication/286000
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:142177964

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy